Quercetin + Fisetin (Senolytic Protocol) — Research Protocol
⚠️ RESEARCH SUMMARY — NOT A TREATMENT PROTOCOL. Discuss all findings with your healthcare provider.
Quercetin (often combined with dasatinib as D+Q) and fisetin are among the most studied senolytic agents. Published research has investigated intermittent dosing regimens. Dosing regimens in published literature vary. This page summarizes published research protocols. It is not a guide for self-treatment. Discuss any treatment decisions with your physician.
Research Dosing (from Published Studies)
| Context | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| D+Q senolytic (research context) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited trial | Kirkland/Mayo published research investigated intermittent regimens. Published studies have investigated various dosing approaches using a brief-exposure approach targeting senescent cells. |
| Fisetin senolytic (AFFIRM trial) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited trial | AFFIRM trial investigated specific regimens. Bioavailability is low — enhanced formulations under development. See cited trial for specific details. |
| Quercetin alone (anti-inflammatory research) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited studies | Research has also investigated non-senolytic anti-inflammatory applications of quercetin. Published studies have investigated various dosing approaches. |
Pharmacokinetics
Quercetin: bioavailability 3-17%. Half-life 3-5 hours. Fisetin: very low oral bioavailability (<10%). Both are rapidly glucuronidated and sulfated. Fat-soluble — absorption improved with dietary fat.
Safety Profile
Quercetin: well tolerated up to 1000mg/day. Mild GI upset possible. Fisetin: limited human safety data at senolytic doses. D+Q: dasatinib component carries hematologic toxicity risk at chronic doses, mitigated by intermittent protocol.
Contraindications
- Dasatinib: pleural effusion history, QT prolongation risk
- Both: caution with anticoagulants
- Fisetin: insufficient pregnancy safety data
- Immunocompromised patients (senescent cells contribute to anti-tumor immunity)
Monitoring Parameters
- CBC with differential before and after each cycle
- Blood pressure monitoring
- Liver function tests quarterly
- Physical function assessment (grip strength, gait speed)
View Quercetin + Fisetin (Senolytic Protocol) glossary entry →